Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IFRX - InflaRx N.V.

IEX Last Trade
2.51
-0.150   -5.976%

Share volume: 1,014
Last Updated: Fri 27 Dec 2024 08:28:46 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.25%

PREVIOUS CLOSE
CHG
CHG%
$2.66
-0.15
-5.64%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 5%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
4.40%
1 Month
8.75%
3 Months
66.24%
6 Months
56.29%
1 Year
44.20%
2 Year
-15.26%
Key data
Stock price
$2.51
P/E Ratio 
0.00
DAY RANGE
$2.58 - $2.66
EPS 
$0.00
52 WEEK RANGE
$1.24 - $2.82
52 WEEK CHANGE
$60.12
MARKET CAP 
93.624 M
YIELD 
N/A
SHARES OUTSTANDING 
58.883 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/30/2024
BETA 
0.39
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$192,560
AVERAGE 30 VOLUME 
$358,978
Company detail
CEO: Niels C. Riedemann
Region: US
Website: inflarx.de
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

InflaRx N.V. discovers and develops inhibitors using C5a technology. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases.

Recent news